# West China Hospital: Observational study in Resectable Hepatocellular Carcinoma (HCC) (380 participants)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | West China Hospital |
| Sponsor type | Academic and hospital |
| Study | Integration of Imaging, Molecular, Pathological, and Clinical Outcome Data in Hepatocellular Carcinoma. |
| NCT ID | NCT07912853 |
| Phase | Observational |
| Status | not yet recruiting |
| Conditions | Resectable Hepatocellular Carcinoma (HCC) |
| Intervention types | procedure |
| Target enrollment | 380 |
| Site countries | China |
| Posted | 2026-11-03 |
| Planned start | 2027-01-01 |
| Event | Newly registered study |
| Event date | 2026-11-03 |

## Why this score
- Posted in the last two weeks.
- 380 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07912853). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.